MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income (loss)
$87,014K
Stock-based compensation
expense
$28,696K
Prepaid expenses and
other current assets
-$4,018K
Non-cash lease expense
$2,410K
Other assets
-$2,056K
Depreciation expense
$1,509K
Net cash provided by
(used in) operating...
$107,505K
Canceled cashflow
$18,198K
Net change in cash,
cash equivalents and...
-$272,516K
Canceled cashflow
$107,505K
Proceeds from exercise of
stock options
$150K
Short-swing profit
settlement
$139K
Proceeds from issuance of
common stock under the...
$138K
Accrued expenses and
other current...
-$10,131K
Accounts payable
-$3,001K
Current income tax
receivable
$2,250K
Right-of-use assets and
operating lease...
$1,978K
Accounts receivable
$825K
Gain on disposal of
fixed asset
$13K
Net cash provided by
(used in) financing...
-$378,470K
Canceled cashflow
$427K
Net cash used in
investing activities
-$1,551K
Repurchase of treasury
stock
$375,000K
Payment of direct
expenses associated with...
$3,897K
Purchase of property and
equipment
$1,551K
Back
Back
Cash Flow
source: myfinsight.com
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)